期刊文献+

替加环素联合注射用头孢哌酮舒巴坦钠对ICU多重耐药菌感染患者症状改善及细菌清除率的影响

Effect of Tigecycline Combined with Cefoperazone Sulbactam Sodium for Injection on Symptom Improvement and Bacterial Clearance in Patients with Multidrug Resistant Bacterial Infection in ICU
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:探讨ICU多重耐药菌感染患者采用替加环素联合头孢哌酮舒巴坦钠(舒普深)治疗的临床疗效。方法:随机将2015年1月~2017年12月收治的88例ICU多重耐药菌感染患者分为两组。A组采用舒普深治疗,B组采用舒普深联合替加环素治疗,比较两组的治疗效果。结果:B组患者体温、肺部啰音、胸部X线平片和白细胞计数等症状体征恢复时间明显短于A组,且B组细菌清除率、治疗总有效率明显高于A组,差异有统计学意义(P<0.05)。结论:ICU多重耐药菌感染患者采用头孢哌酮舒巴坦钠联合替加环素治疗,能有效改善患者的症状体征,清除细菌,促进患者康复。 Objective:To discuss clinical efficacy of tigecycline combined with cefoperazone sulbactam sodium(sulperazone)in ICU patients with multi-drug resistant bacterial infections.Methods:88 patients with multidrug resistant bacterial infections admitted in ICU from January 2015 to December 2017 were randomly divided into two groups.Group A was treated with sulperazone and group B was treated with sulperazone combined with tigecycline.The therapeutic effects of the two groups were compared.Results:The recovery time of body temperature,lung rales,chest X-ray plain film and white blood cell count in group B was significantly shorter than that in group A,and the bacterial clearance rate and total effective rate in group B were significantly higher than that in group A,the difference was statistically significant(P<0.05).Conclusion:The combination of cefoperazone sulbactam sodium and tigecycline can effectively improve the symptoms and signs of patients with multidrug resistant bacterial infections in ICU,eliminate bacteria and promote the rehabilitation of patients.
作者 许清琴 Xu Qingqin(Department of Internal Medicine,Ruzhou No.1 People's Hospital,Pingdingshan 467599)
出处 《数理医药学杂志》 2020年第3期407-409,共3页 Journal of Mathematical Medicine
关键词 ICU 多重耐药菌感染 替加环素 头孢哌酮舒巴坦钠 疗效 ICU multidrug-resistant bacteria infection tigecycline cefoperazone sulbactam sodium curative effect
  • 相关文献

二级参考文献43

共引文献38

论文智能改写系统
维普数据出版直通车
投稿分析
职称考试

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈